Moffitt Cancer Center Teams with CvergenX on Radiotherapy Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Moffitt Cancer Center and diagnostics service firm CvergenX announced today an exclusive worldwide licensing agreement covering CvergenX's radiation therapy technology platform called InterveneXRT.

In a statement, Moffitt said that its researchers have used gene expression analysis and system biology "to create a radio-sensitivity classification index for individual tumors."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.